Results 241 to 250 of about 468,662 (346)

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

open access: yesAdvanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun   +23 more
wiley   +1 more source

Hyperviscous Diabetic Bone Marrow Niche Impairs BMSCs Osteogenesis via TRPV2‐Mediated Cytoskeletal‐Nuclear Mechanotransduction

open access: yesAdvanced Science, EarlyView.
Diabetic bone marrow exhibits pathological ECM hyperviscosity that activates TRPV2‐mediated Ca2⁺ influx, leading to perinuclear F‐actin disassembly, nuclear deformation, and chromatin condensation. This cytoskeletal‐nuclear decoupling suppresses osteogenic differentiation of BMSCs.
Yao Wen   +8 more
wiley   +1 more source

Variational adversarial negative sampling for multimodal knowledge graph completion

open access: hybrid
H. Miao   +5 more
openalex   +1 more source

DEL‐1 is an Endogenous Senolytic Protein that Inhibits Senescence‐Associated Bone Loss

open access: yesAdvanced Science, EarlyView.
Senescent bone marrow stromal cells accumulate in the aging bone microenvironment, promoting bone degeneration. DEL‐1, an endogenous secreted protein, acts as a natural senolytic that selectively eliminates these cells. By engaging a β3 integrin/CD73/adenosine/p38 MAPK/BCL‐2 pathway, DEL‐1 counters aging‐related bone loss, revealing promising ...
Jong‐Hyung Lim   +11 more
wiley   +1 more source

An explainable path reasoning framework for knowledge graph completion

open access: gold
Haiyang Yu   +5 more
openalex   +1 more source

Home - About - Disclaimer - Privacy